Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Dendreon FDA Deadline Set For May 1
|
Luke Timmerman |
11/20/09 |
Seattle
|
|
Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore
|
Luke Timmerman |
11/19/09 |
Boston
|
|
FDA Shoots Down Genzyme’s Latest Bid for Pompe Drug Approval
|
Ryan McBride |
11/16/09 |
Boston
|
|
Alkermes to Seek FDA Approval of Anti-Addiction Drug
|
Ryan McBride |
11/16/09 |
Boston
|
|
Cadence Hit By FDA Delay
|
Luke Timmerman |
11/13/09 |
San Diego
|
|
Genzyme Shares Tank After FDA Discovers Bits of Steel, Rubber in Five Different Drugs
|
Luke Timmerman |
11/13/09 |
Boston
|
|
Ironwood Nabs $75M in Deal With Japanese Firm, Gloucester Drug Gets FDA Approval, Alnylam Branches Into Biomanufacturing Tech, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
11/13/09 |
Boston
|
|
Trius Therapeutics Reveals Plans for IPO, SpectraScience Raises $4.3M, Sequenom Tightens its Belt, & More San Diego Life Sciences News
|
Denise Gellene |
11/12/09 |
San Diego
|
|
Alder and New Partner, Bristol, to Give Amgen and Abbott a Run for Their Money
|
Luke Timmerman |
11/11/09 |
Seattle
|
|
BioVex Nails Down Another $30M To Finish Pivotal Study of Cancer-Killing Virus
|
Luke Timmerman |
11/10/09 |
Boston
|
|
ZymoGenetics, King Pharma Brawl Over Drugs to Control Surgical Bleeding
|
Luke Timmerman |
11/09/09 |
Seattle
|
|
Gloucester Pharma Wins FDA Approval of Drug for Rare Skin Cancer
|
Luke Timmerman |
11/05/09 |
Boston
|
|
Dendreon Files FDA Application, DxBox Reaches Turning Point, ISB to Do 100 Genomes, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
11/05/09 |
Seattle
|
|
Amylin Forms Global Alliance in Obesity Drug Development; TEDMED’s Show Will Go On, Sequenom Sued for Civil Fraud, & More San Diego Biotech News
|
Bruce V. Bigelow |
11/05/09 |
San Diego
|
|
Vertex and Ironwood Drugs Fare Well in Clinical Trials, Pulmatrix Breathes in $30.2M, IRobot Launches Healthcare Unit, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
11/04/09 |
Boston
|
|
Dendreon Files Provenge Application to FDA Ahead of Schedule, Now It’s Time to Wait
|
Luke Timmerman |
11/02/09 |
Seattle
|
|
Amylin, Lilly’s Byetta Wins FDA Approval as Standalone Therapy, Without Combo Drugs
|
Luke Timmerman |
10/30/09 |
San Diego
|
|
UK’s Enigma Looks to San Diego, Life Gets Sweeter for Senomyx, Arena Says Obesity Drug Is Not “Wimpy,” & More San Diego Life Sciences News
|
Denise Gellene |
10/29/09 |
San Diego
|
|
Stryker Biotech Division Indicted for FDA Fraud by Massachusetts Grand Jury
|
Luke Timmerman |
10/28/09 |
Boston
|
|
Interlace Gets FDA Clearance
|
Ryan McBride |
10/28/09 |
Boston
|
|
UK’s Enigma Diagnostics to Establish U.S. Headquarters in San Diego
|
Bruce V. Bigelow |
10/27/09 |
San Diego
|
|
Arena Positions Weight Loss Drug as the One That Won’t Raise Your Blood Pressure
|
Luke Timmerman |
10/27/09 |
San Diego
|
|
ZymoGenetics’ Former Medical Boss Leads Rival Startup, ProFibrix, With Drug For Bleeding
|
Luke Timmerman |
10/26/09 |
Seattle
|
|
Five Red Flags of a Biotech, Pathway Medical Learns Lessons, Amgen Faces FDA Delay, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/22/09 |
Seattle
|
|
Antigenics Shares Plummet as Cancer Vaccine Application Rejected in Europe
|
Luke Timmerman |
10/21/09 |
Boston
|
|
Pathway Medical Learns Lessons During Tougher Than Expected First Year on Market
|
Luke Timmerman |
10/20/09 |
Seattle
|
|
Amgen’s Dmab Faces FDA Delay
|
Luke Timmerman |
10/19/09 |
Seattle
|
|
Top 10 Highlights from FiReGlobal: Michael Dell, Lee Hartwell, Irwin Jacobs, and More
|
Gregory T. Huang |
10/16/09 |
Seattle
|
|
Alkermes Anti-Addiction Drug Fares Well in Clinical Trials, Amgen Takes Aim at Drug-Development Success Rate, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
10/14/09 |
Boston
|
|
Six Tips on How to Spot a Winning Biotech, From Dendreon Co-Founder Chris Henney
|
Luke Timmerman |
10/14/09 |
Seattle
|
|
Page 1 of
14 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
